Deepak Sree, MD
Rheumatology · Huntsville, ALNPI 1235391988
Payments from drug & device makers
Across 1,071 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$3K
- UCB, Inc.$1K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$980
- plus $5K from 30 others
What the payments were for
- Food & beverage$16,453100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 274 | $4,510 |
| Amgen(2 entities) | 178 | $2,650 |
| UCB, Inc. | 119 | $1,352 |
| Novartis | 84 | $1,094 |
| E.r. Squibb & Sons, L.L.C. | 83 | $1,048 |
| Johnson & Johnson(2 entities) | 65 | $980 |
| GSK | 48 | $873 |
| Pfizer | 36 | $466 |
| AstraZeneca(2 entities) | 23 | $420 |
| Radius Health, Inc. | 26 | $382 |
| Boehringer Ingelheim | 14 | $320 |
| Aurinia Pharma U.S., Inc. | 15 | $310 |
| Genentech USA, Inc. | 24 | $303 |
| Mallinckrodt Enterprises LLC | 11 | $270 |
| Mallinckrodt Hospital Products Inc. | 7 | $265 |
| Bristol Myers Squibb | 10 | $251 |
| Fresenius Kabi USA, LLC | 17 | $233 |
| Arbor Pharmaceuticals, Inc. | 2 | $139 |
| Lilly USA, LLC | 9 | $135 |
| Sanofi | 4 | $112 |
| Actelion Pharmaceuticals US, Inc. | 4 | $47 |
| Janssen Scientific Affairs, LLC | 1 | $40 |
| Antares Pharma, Inc. | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Tersera Therapeutics LLC | 1 | $26 |
| Mylan Institutional Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Celltrion USA Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Avion Pharmaceuticals | 1 | $14 |
| Merck | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,505 in reported general payments places this provider in the 65th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 77 | $904,803 |
| Enbrel SureclickEtanercept | 77 | $592,765 |
| Orencia ClickjectAbatacept | 93 | $560,215 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $259,261 |
| XeljanzTofacitinib Citrate | 27 | $165,621 |
| RinvoqUpadacitinib | 25 | $155,062 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $104,191 |
| Teriparatide | 24 | $70,657 |
| ForteoTeriparatide | 12 | $66,710 |
| BenlystaBelimumab | 11 | $62,906 |
| Hydroxychloroquine Sulfate | 719 | $28,700 |
| RasuvoMethotrexate/Pf | 23 | $24,831 |
| Duloxetine Hcl | 719 | $12,461 |
| MethotrexateMethotrexate Sodium | 493 | $11,146 |
| Gabapentin | 636 | $7,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $21 | $259,26125 claims |
| PfizerXeljanz | $466 | $165,62127 claims |
| AbbVieRinvoq | $4,510 | $155,06225 claims |
| Lilly USA, LLCForteo | $135 | $66,71012 claims |
| GSKBenlysta | $873 | $62,90611 claims |
| Medexus Pharma, Inc.Rasuvo | $11 | $24,83123 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $30 | $5,07741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Huntsville
- William ShergyHuntsville$453K
- Kun ChenHuntsville$22K
- Ayesha JaleelHuntsville$14K
- Margaret MeehanHuntsville$13K
- Christie ThomasHuntsville$12K
- Roxanna SabghiHuntsville$11K
- Robert PhillipsHuntsville$7K
- Elijah MitchamHuntsville$5K
- Jeffrey CurtisBirmingham$17.6M
- Kenneth SaagBirmingham$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.